June 2017 in “Poster presentations” All four treatments for early rheumatoid arthritis had similar safety profiles.
February 2024 in “Reactions weekly” 10 citations
,
January 2012 in “Case reports in medicine” Diphencyprone can cause unexpected and possibly permanent vitiligo.
July 2022 in “British Journal of Dermatology”
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
1 citations
,
June 2025 in “European Journal of Clinical Pharmacology” Finasteride may increase the risk of suicidality and depression, especially in younger people.
3 citations
,
April 1977 in “PubMed” The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
4 citations
,
December 1994 in “PubMed” Cyproterone acetate with estradiol improved women's self-confidence and emotional well-being without a difference between oral or transdermal methods, but younger women preferred the oral method.
April 2025 in “European Psychiatry” Mood stabilizers for bipolar disorder can cause skin issues, but severe reactions are rare.
29 citations
,
January 2016 in “CNS drugs” Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
January 2024 in “Case Reports in Dermatological Medicine” Baricitinib may effectively treat nail changes in alopecia areata.
8 citations
,
August 2018 in “BMJ Case Reports” Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
March 2025 in “SKIN The Journal of Cutaneous Medicine” July 2023 in “SKIN The Journal of Cutaneous Medicine” Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
April 2010 in “Nature Reviews Urology”
December 2025 in “International Neurourology Journal” Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
17 citations
,
May 2007 in “Forensic Science Medicine and Pathology” Clozapine levels in hair reflect dosage and bind more to pigmented hair.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
148 citations
,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
March 2023 in “Translational Andrology and Urology” 5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
3 citations
,
April 2022 in “Neuroscience Letters” Finasteride may help treat autism by reducing inflammation and oxidative stress.
December 2003 in “British Journal of Urology”